CLSD - Clearside Biomedical, Inc.
| Previous close | 1.0800 |
| Open | 1.0600 |
| Bid | 1.1400 x 800 |
| Ask | 1.1500 x 1400 |
| Day's range | 1.0593 - 1.1600 |
| 52-week range | 0.9000 - 1.8550 |
| Volume | |
| Avg. volume | 179,304 |
| Market cap | 70.299M |
| Beta (5Y monthly) | 2.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -7.14% and 98.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Clearside Biomedical, Inc. (CLSD) Reports Q3 Loss, Lags Revenue Estimates
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -425% and 98.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Wave Life Sciences (WVE) Soars 13.8%: Is Further Upside Left in the Stock?
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of 0% and 48.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of 8.33% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
